References
- JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin20106027730020610543
- SiegelRWardEBrawleyOJemalACancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin20116121223621685461
- HowladerNNooneAMKrapchoMSEER Cancer Statistics Review 1975–2008National Cancer InstituteBethesda, MD Available from: http://seer.cancer.gov/csr/1975_2008/Accessed September 20, 2011
- BalchCMGershenwaldJESoongSJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol2009276199620619917835
- National Comprehensive Cancer NetworkMelanoma2012 Available from: http://www.nccn.org/index.aspAccessed October 28, 2011
- BarthAWanekLAMortonDLPrognostic factors in 1,521 melanoma patients with distant metastasesJ Am Coll Surg19951811932017670677
- HodiFSObleDADrappatzJCTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNSNat Clin Pract Oncol2008555756118665147
- MargolinKADi GiacomoAMMaioMBrain metastasis in melanoma: clinical activity of CTLA-4 antibody therapySemin Oncol20103746847221074062
- RadbillAEFiveashJFFalkenbergETInitial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicityCancer200410182583315305416
- StaudtMLasithiotakisKLeiterUDeterminants of survival in patients with brain metastases from cutaneous melanomaBr J Cancer2010101213121820372154
- DummerRMaioMHamidOAbstract P-0004 presented at the Perspectives in Melanoma XIV meetingAmsterdam, The NetherlandsSeptember 17–18, 2010
- IvesNJStoweRLLoriganPWheatleyKChemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patientsJ Clin Oncol2007255426543418048825
- AgarwalaSSCurrent systemic therapy for metastatic melanomaExpert Rev Anticancer Ther2009958759519445576
- ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med20113642507251621639808
- Zelboraf® (vemurafenib) package insertSouth San Francisco, CAGenentech USA Inc2011
- HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
- HoosAIbrahimRKormanADevelopment of ipilimumab: contribution to a new paradigm for cancer immunotherapySemin Oncol201037553354621074069
- RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med20113642517252621639810
- Yervoy™ (ipilimumab) package insertPrinceton, NJBristol-Myers Squibb Company2011
- IbrahimRBermanDde PrilVIpilimumab safety profile: summary of findings from completed trials in advanced melanomaJ Clin Oncol201129SupplAbstract 8583
- Bristol-Myers SquibbIpilimumab US prescribing information: risk evaluation and mitigation strategy (REMS) Available from: http://www.yervoy.com/hcp/rems.aspxAccessed September 12, 2011
- WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res2009157412742019934295
- HoosAEggermontAMJanetzkiSImproved endpoints for cancer immunotherapy trialsJ Natl Cancer Inst20101021388139720826737